Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers.

Authors:
Hagström H; Yan J; Talbäck M; Andreasson A; Walldius G and 2 more

Journal:
Aliment Pharmacol Ther

Publication Year: 2022

DOI:
10.1111/apt.17374

PMCID:
PMC10107149

PMID:
36566508

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic…
Wijarnpreecha K; Li F; Lundin SK and 5 more (2023) - Transparency Score: 3/6
Longer time to recovery from acute kidney injury is associated with major adverse kidney events in …
Patidar KR; Naved MA; Kabir S and 9 more (2023) - Transparency Score: 3/6
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for s…
Hermann RP; Rockey DC; Suzuki A and 2 more (2022) - Transparency Score: 3/6
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disea…
Meade S; Patel KV; Luber RP and 17 more (2022) - Transparency Score: 4/6
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogas…
Visaggi P; Ghisa M; Del Corso G and 11 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST This study was directly supported by a research grant from Astra Zeneca to HH:s institution."

Evidence found in paper:

"FUNDING INFORMATION HH was further supported by grants from the Swedish Research Council, the Swedish Cancer Society, Radiumhemmet Research Foundation and Region Stockholm. HH: institution has received research grants from Gilead, Intercept, EchoSens, MSD and Pfizer unrelated to the current study."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025